Royalty Report: Drugs, Disease, Cancer – Collection: 286043

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Disease
  • Cancer
  • Therapeutic
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 286043

License Grant
Licensor hereby grants to Licensee an exclusive sublicense under the Licensed Patents in the Field of Use to make and have made, manufacture and have manufactured Agreement Compounds and Licensed Products from Agreement Compounds for sale in the Territory and to use and have used and lease, sell and have sold Licensed  Products, and to practice the Licensed Processes, and Improvements, with the right to grant sublicenses (with the prior written consent of Licensor, which consent shall not be unreasonably withheld), in the Territory and Licensor further grants to Licensee an exclusive sublicense  to use the Know-How to make and have made, manufacture  and have manufactured Agreement Compounds and Licensed Products from Agreement Compounds for sale in the Territory and to use the Know-How to use and hav  used and lease, sell and have sold Licensed Products, and to practice the Licensed Processes, and Improvements, with the right to grant sublicenses (with the prior written consent of Licensor, which consent shall not be unreasonably withheld), in the Territory.
License Property
Licensed Patents means all of the intellectual property, granted to Licensor identified herein as Agreement  Compounds for the described Field of Use.

Patent Application # U.S.S.N. 60/073,603 entitled 'N,N-Bis(2-Hydroxybenzyl) Ethylenediamine-N,N-Diacetic Acid in Iron Chelating Theraphy'.

Agreement  Compounds means the monosodium salt of N,N-bis (2-hydroxybenzyl) ethylenediamine-N,N diacetic acid (hereinafter 'NaHBED' or 'HBED'), or any other mono-cation salt of HBED.

Licensed Products means any product or part thereof which:
(a) is  covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Licensed  Patents in the country in which any Licensed Products are made, used or sold;
(b) is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Licensed Patents in the country in which any Licensed Process is used or in which such product or part thereof is used or sold;
(c) is derived from Licensed  Patents, Know-How and/or trade secrets related to or described in the Licensed Patents; (d) is sold, manufactured or used in any country under this Agreement; and/or
(e) contains Agreement Compounds in final packaged form suitable for distribution to non-affiliated customers and bears Licensees or Licensees Affiliates typical trade dress.

Intellectual property relates to develop and market a proprietary iron chelator.  Iron chelation therapy is the removal of excess iron from the body with special drugs.

Field of Use
Field of Use means iron overload conditions, including, but not limited to, Thalassemia, sickle-cell anemia, and myelodysplasia (but excluding neuro- degenerative disorders), but shall exclude uses of Agreement Compounds by a route of delivery other than subcutaneous or IM injection or IV infusion or transdermal.

Thalassemia is a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia.

Sickle cell anemia is an inherited form of anemia — a condition in which there aren't enough healthy red blood cells to carry adequate oxygen throughout your body.

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.

IPSCIO Record ID: 263341

License Grant
Licensor, an individual, hereby grants and Licensee hereby accepts an exclusive, sublicenseable, royalty-bearing license for use of Licensor Technology to make, have made, use, offer for sale, export, import, and sell Licensed Products, in the licensed field of use in the licensed territory during the term.
License Property
Licensor owns inter alia certain patent rights, trade secrets, know how, and other proprietary information and technology related to the use of soluble ferric pyrophosphate (“SFP”) including for use in management of iron disorders including preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia.

TPN TRIFERIC® is a total parenteral nutrituional (TPN) product incorporating SFP (soluble ferric pyrophosphate)  including those for replacement/maintenance of iron, management of iron disorders,  preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia in any and all indications where SFP, delivered by TPN, may be useful.

Licensor owns certain patent rights, trade secrets, know how, and other proprietary information and technology related to the  use of soluble ferric pyrophosphate (“SFP”) including for use in management of iron disorders including preventing and treating medical conditions such as absolute or functional iron deficiency and iron deficiency anemia.
Iron deficiency anemia is a common type of anemia — a condition in which blood lacks adequate healthy red blood cells. Red blood cells carry oxygen to the body's tissues.

Licensor Patent Rights means the patent applications and patents listed; and continuing applications thereof including divisions, substitutions, extensions and continuation-in-part applications; any patents issuing on said applications or continuing applications including reissues and re-examined applications and any corresponding foreign patents or applications; as well as any patent term extensions or adjustments thereof; to the extent the above covers or applies to Licensed Products.
Patent:
9,161,951 – United States – Issue Date 10/20/2015 – Parenteral nutrition composition containing iron

Licensed Products means all compositions of matter, formulations, articles of manufacture, materials, and products using, including, comprising or incorporating SFP or any specific species thereof, including generics, in the licensed field of use that incorporate the Licensor Technology.

Licensor Technology means subject matter disclosed, described or claimed in Licensor Patent Rights and Licensor Know How that has been documented prior to the effective date.

Field of Use
Licensed Field of Use is limited to only TPN formulations of SFP and TPN formulations of specific species of SFP, and indications treated by such TPN formulations of SFP and its specific species. For clarity, the licensed field of use expressly excludes non-IV formulations for instance delivery of SFP via a dialysate solution which is the subject of the 2002 Agreement as amended. SFP formulations for other modes of delivery, e.g., transdermal, shall require additional licenses, which the parties shall negotiate in good faith should the occasion arise; and Licensee shall have no implied or actual license or other right to exploit or commercialize any non-TPN formulations for delivery of SFP through any such other modes of delivery which are based in any manner upon Licensor Technology.

Triferic is a revolutionary iron therapy that replaces iron and maintains hemoglobin without increasing iron stores, and Triferic is the only FDA approved product indicated to replace iron and maintain hemoglobin concentration in adult HDD-CKD hemodialysis patients.

IPSCIO Record ID: 230759

License Grant
The University grants the non-exclusive right and license to make, have made, use, lease and sell the Licensed Products, and to practice the Licensed Processes in the Territory for the Fields of Use to the end of the term for which the Patent Rights are granted unless sooner terminated according to the terms hereof.
License Property
The patent is for AAV Transduction Vectors.

A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.

A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or,  is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.

Field of Use
The Fields of Use shall mean:
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].

(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].

c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].

(d) All human [infectious diseases other than HIV]. This Field includes: [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.

IPSCIO Record ID: 256305

License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensor Patents, the Isis Splicing Patents and/or the Licensee Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.

The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.

Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).

Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

IPSCIO Record ID: 256513

License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensee Patents, the Isis Splicing Patents and/or the Licensor Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.

The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.

Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).

Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.